CBAS1
MCID: BLC007
MIFTS: 43

Bile Acid Synthesis Defect, Congenital, 1 (CBAS1)

Categories: Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Bile Acid Synthesis Defect, Congenital, 1

MalaCards integrated aliases for Bile Acid Synthesis Defect, Congenital, 1:

Name: Bile Acid Synthesis Defect, Congenital, 1 57 29 13 6 44 73
Cbas1 57 12 53 25 75
3-Beta-Hydroxy-Delta-5-C27-Steroid Oxidoreductase Deficiency 57 53 59 75
Congenital Bile Acid Synthesis Defect Type 1 53 25 59
Congenital Bile Acid Synthesis Defect 1 12 75 15
Basd1 53 59
3-Alpha Beta-Hydroxy-Delta-5-C27-Steroid Oxidoreductase, Deficiency of 53
3beta-Hydroxy-Delta-5-C27-Steroid Oxidoreductase Deficiency 25
3beta-Hydroxy-Delta-5-C27-Steroid Dehydrogenase Deficiency 25
Progressive Familial Intrahepatic Cholestasis Type 4 75
3-Beta-Hydroxy-Delta-5-C27-Steroid Oxidoreductase 13
Cholestasis, Progressive Familial Intrahepatic 4 73
Bile Acid Synthesis Defect, Congenital, Type 1 40
Congenital Bile Acid Synthesis Defect, Type 1 53
Neonatal Progressive Intrahepatic Cholestasis 75
3beta-Hsdh Deficiency 25
Pfic4 75

Characteristics:

Orphanet epidemiological data:

59
congenital bile acid synthesis defect type 1
Inheritance: Autosomal recessive; Age of onset: Infancy,Neonatal; Age of death: any age;

OMIM:

57
Inheritance:
autosomal recessive

Miscellaneous:
neonatal onset
favorable response to oral bile acid therapy
caused by inborn error in bile acid synthesis


HPO:

32
bile acid synthesis defect, congenital, 1:
Onset and clinical course neonatal onset
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Bile Acid Synthesis Defect, Congenital, 1

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 79301Disease definitionCongenital bile acid synthesis defect type 1 (BAS defect type 1) is the most common anomaly of bile acid synthesis (see this term) characterized by variable manifestations of progressive cholestatic liver disease, and fat malabsorption.EpidemiologyPrevalence is unknown but may be around 1-9/1,000,000 for overall BAS defects, excluding cerebrotendinous xanthomatosis.Clinical descriptionThe clinical presentation is heterogeneous, however most patients present with features of neonatal cholestasis. Clinical features include hepatomegaly with or without splenomegaly, jaundice, fat and fat-soluble vitamin malabsorption, and mild steatorrhea. In most cases, pruritus is absent. Liver function tests present elevated serum transaminases (AST, ALT), conjugated hyperbilirubinemia, and normal gamma-GT. The liver histology shows inflammation, giant cells, evidence of cholestasis, and variable degrees of liver fibrosis. The clinical course of early-onset disease is heterogeneous with some patients resolving jaundice and being identified later in life, or with more fulminant disease that results in death or requires liver transplantation at an early age. The disorder may also present as late-onset chronic cholestasis. In such patients, liver disease is not always evident and patients may have fat-soluble vitamin malabsorption with rickets, corrected by vitamin supplementation, and/or other complications including bleeding diathesis (hematochezia or intracranial bleeding), neuroaxonal dystrophy and night blindness. Serum liver enzymes are initially often normal but later show increases with progression of liver disease to fibrosis. Children and adolescents may also present with extensive fibrosis and/or cirrhosis.EtiologyThe disease is caused by a mutation in the gene encoding 3-beta-hydroxy-delta-5-C27 steroid oxidoreductase (HSD3B7, 16p12-p11.2). Transmission is autosomal recessive.Diagnostic methodsDiagnosis is based on detection of sulfate and glycosulfate conjugates of 3-beta-hydroxy-delta-5 bile acids, which are the signature metabolites of this bile acid defect, on liquid secondary ionization mass spectrometry (LSIMS) analysis of urine. Gas chromatography - mass spectrometry (GC-MS) or electroscopy and tandem mass spectrometry may also be used.Differential diagnosisDifferential diagnoses include progressive familial intrahepatic cholestasis, diseases that present with neonatal cholestasis, which includes alpha-1-antitrypsin deficiency of ZZ phenotype, Alagille syndrome, biliary atresia, cystic fibrosis, and metabolic diseases (tyrosinemia type I, galactosemia, hereditary fructose intolerance) (see these terms), diseases that present with fat and fat soluble vitamin malabsorption, including other liver diseases, and intestinal disease, or diseases that present with growth failure.Antenatal diagnosisAntenatal diagnosis can be made on embryonic tissue obtained when there has been a previously identified sibling. Urine LSIMS in a suspect infant can confirm the diagnosis in the first neonatal days.Management and treatmentTreatment is based on oral administration of cholic acid which leads to gradual resolution of biochemical and histologic abnormalities and prevents progression of the disease, even in cases with hepatic fibrosis and cirrhosis. Cholic acid therapy stimulates bile flow and suppresses synthesis of atypical bile acids and production of toxic intermediates via the bile acid pathway linked to the pathogenesis of disease.PrognosisWith early treatment the long-term prognosis is excellent.Visit the Orphanet disease page for more resources.

MalaCards based summary : Bile Acid Synthesis Defect, Congenital, 1, also known as cbas1, is related to cholestasis, progressive familial intrahepatic, 4 and congenital bile acid synthesis defect, and has symptoms including diarrhea and icterus. An important gene associated with Bile Acid Synthesis Defect, Congenital, 1 is HSD3B7 (Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta- And Steroid Delta-Isomerase 7), and among its related pathways/superpathways are Neuroscience and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Doxorubicin and Doxil have been mentioned in the context of this disorder. Affiliated tissues include liver and testes, and related phenotypes are failure to thrive and splenomegaly

Disease Ontology : 12 A congenital bile acid synthesis defect characterized by progressive cholestatic liver disease, giant cell hepatitis, malabsorption of fat and fat-soluble vitamins, increased serum bilirubin and decreased serum cholesterol that has material basis in homozygous or compound heterozygous mutation in the HSD3B7 gene on chromosome 16p.

Genetics Home Reference : 25 Congenital bile acid synthesis defect type 1 is a disorder characterized by cholestasis, a condition that impairs the production and release of a digestive fluid called bile from liver cells. Bile is used during digestion to absorb fats and fat-soluble vitamins, such as vitamins A, D, E, and K. People with congenital bile acid synthesis defect type 1 cannot produce (synthesize) bile acids, which are a component of bile that stimulate bile flow and help it absorb fats and fat-soluble vitamins. As a result, an abnormal form of bile is produced.

OMIM : 57 Congenital defects of bile acid synthesis are autosomal recessive disorders characterized by neonatal onset of progressive liver disease with cholestatic jaundice and malabsorption of lipids and lipid-soluble vitamins from the gastrointestinal tract resulting from a primary failure to synthesize bile acids. Affected infants show failure to thrive and secondary coagulopathy. In most forms of the disorder, there is a favorable response to oral bile acid therapy (summary by Cheng et al., 2003). (607765)

UniProtKB/Swiss-Prot : 75 Congenital bile acid synthesis defect 1: A primary defect in bile synthesis leading to progressive liver disease. Clinical features include neonatal jaundice, severe intrahepatic cholestasis, cirrhosis.

Related Diseases for Bile Acid Synthesis Defect, Congenital, 1

Graphical network of the top 20 diseases related to Bile Acid Synthesis Defect, Congenital, 1:



Diseases related to Bile Acid Synthesis Defect, Congenital, 1

Symptoms & Phenotypes for Bile Acid Synthesis Defect, Congenital, 1

Symptoms via clinical synopsis from OMIM:

57
Growth Other:
failure to thrive

Abdomen External Features:
hepatomegaly
cirrhosis
jaundice
intrahepatic cholestasis
progressive liver failure
more
Abdomen Gastrointestinal:
diarrhea
steatorrhea
malabsorption of fat and fat-soluble vitamins
discolored, acholic stools

Hematology:
coagulopathy secondary to liver disease

Abdomen Spleen:
splenomegaly

Skin Nails Hair Skin:
jaundice

Laboratory Abnormalities:
abnormal liver function tests
decreased serum cholesterol
increased serum bilirubin
normal serum levels of gamma-ggt


Clinical features from OMIM:

607765

Human phenotypes related to Bile Acid Synthesis Defect, Congenital, 1:

59 32 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 failure to thrive 59 32 hallmark (90%) Very frequent (99-80%) HP:0001508
2 splenomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0001744
3 hepatomegaly 59 32 hallmark (90%) Very frequent (99-80%) HP:0002240
4 malabsorption 59 32 hallmark (90%) Very frequent (99-80%) HP:0002024
5 osteoporosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000939
6 pruritus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000989
7 peripheral neuropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0009830
8 cirrhosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001394
9 jaundice 59 32 hallmark (90%) Very frequent (99-80%) HP:0000952
10 nyctalopia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000662
11 biliary tract abnormality 59 32 hallmark (90%) Very frequent (99-80%) HP:0001080
12 gastrointestinal hemorrhage 59 32 frequent (33%) Frequent (79-30%) HP:0002239
13 abnormality of coagulation 59 32 frequent (33%) Frequent (79-30%) HP:0001928
14 neonatal cholestatic liver disease 59 32 hallmark (90%) Very frequent (99-80%) HP:0006566
15 abnormal bleeding 59 Occasional (29-5%)
16 elevated hepatic transaminases 59 Very frequent (99-80%)
17 diarrhea 32 HP:0002014
18 hepatic failure 32 HP:0001399
19 hyperbilirubinemia 32 HP:0002904
20 acholic stools 32 HP:0011985
21 abnormality of the coagulation cascade 32 HP:0003256
22 intrahepatic cholestasis 32 HP:0001406
23 steatorrhea 32 HP:0002570
24 hypocholesterolemia 32 HP:0003146
25 giant cell hepatitis 32 HP:0200084
26 elevated hepatic transaminase 32 hallmark (90%) HP:0002910

UMLS symptoms related to Bile Acid Synthesis Defect, Congenital, 1:


diarrhea, icterus

GenomeRNAi Phenotypes related to Bile Acid Synthesis Defect, Congenital, 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased caspase 3/7 activity GR00318-A 8.62 GRIN2A GRIN2B

Drugs & Therapeutics for Bile Acid Synthesis Defect, Congenital, 1

Drugs for Bile Acid Synthesis Defect, Congenital, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
2
Doxil Approved June 1999 Phase 1 31703
3 Antibiotics, Antitubercular Phase 1
4 Topoisomerase Inhibitors Phase 1
5 Anti-Bacterial Agents Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin Recruiting NCT03002805 Phase 1 CBT-1®
2 Acute Gastrointestinal Tolerability Following a Single Serving of a Novel Dietary Fiber Completed NCT02530762 Not Applicable
3 Gastrointestinal Tolerability Following Multiple Servings of a Novel Dietary Fiber Completed NCT02532985 Not Applicable

Search NIH Clinical Center for Bile Acid Synthesis Defect, Congenital, 1

Cochrane evidence based reviews: bile acid synthesis defect, congenital, 1

Genetic Tests for Bile Acid Synthesis Defect, Congenital, 1

Genetic tests related to Bile Acid Synthesis Defect, Congenital, 1:

# Genetic test Affiliating Genes
1 Bile Acid Synthesis Defect, Congenital, 1 29 HSD3B7

Anatomical Context for Bile Acid Synthesis Defect, Congenital, 1

MalaCards organs/tissues related to Bile Acid Synthesis Defect, Congenital, 1:

41
Liver, Testes

Publications for Bile Acid Synthesis Defect, Congenital, 1

Articles related to Bile Acid Synthesis Defect, Congenital, 1:

# Title Authors Year
1
[3 beta-hydroxy-delta 5-C27-steroid-oxidoreductase/isomerase deficiency]. ( 9645061 )
1998

Variations for Bile Acid Synthesis Defect, Congenital, 1

UniProtKB/Swiss-Prot genetic disease variations for Bile Acid Synthesis Defect, Congenital, 1:

75
# Symbol AA change Variation ID SNP ID
1 HSD3B7 p.Gly19Ser VAR_054775
2 HSD3B7 p.Glu147Lys VAR_054776 rs104894518

ClinVar genetic disease variations for Bile Acid Synthesis Defect, Congenital, 1:

6 (show all 14)
# Gene Variation Type Significance SNP ID Assembly Location
1 HSD3B7 NM_025193.3(HSD3B7): c.1039_1040delCT (p.Leu347Valfs) deletion Pathogenic rs397514442 GRCh37 Chromosome 16, 30999433: 30999434
2 HSD3B7 NM_025193.3(HSD3B7): c.1039_1040delCT (p.Leu347Valfs) deletion Pathogenic rs397514442 GRCh38 Chromosome 16, 30988112: 30988113
3 HSD3B7 NM_025193.3(HSD3B7): c.294dupC (p.Lys99Glnfs) duplication Pathogenic rs397514443 GRCh37 Chromosome 16, 30997497: 30997497
4 HSD3B7 NM_025193.3(HSD3B7): c.294dupC (p.Lys99Glnfs) duplication Pathogenic rs397514443 GRCh38 Chromosome 16, 30986176: 30986176
5 HSD3B7 NM_025193.3(HSD3B7): c.322+1G> T single nucleotide variant Pathogenic rs387906288 GRCh37 Chromosome 16, 30997526: 30997526
6 HSD3B7 NM_025193.3(HSD3B7): c.322+1G> T single nucleotide variant Pathogenic rs387906288 GRCh38 Chromosome 16, 30986205: 30986205
7 HSD3B7 NM_025193.3(HSD3B7): c.439G> A (p.Glu147Lys) single nucleotide variant Pathogenic rs104894518 GRCh37 Chromosome 16, 30997933: 30997933
8 HSD3B7 NM_025193.3(HSD3B7): c.439G> A (p.Glu147Lys) single nucleotide variant Pathogenic rs104894518 GRCh38 Chromosome 16, 30986612: 30986612
9 HSD3B7 NM_025193.3(HSD3B7): c.45_46delAG (p.Gly17Leufs) deletion Pathogenic rs786200876 GRCh37 Chromosome 16, 30997024: 30997025
10 HSD3B7 NM_025193.3(HSD3B7): c.45_46delAG (p.Gly17Leufs) deletion Pathogenic rs786200876 GRCh38 Chromosome 16, 30985703: 30985704
11 HSD3B7 NM_025193.3(HSD3B7): c.890delT (p.Phe297Serfs) deletion Pathogenic rs886043511 GRCh37 Chromosome 16, 30999284: 30999284
12 HSD3B7 NM_025193.3(HSD3B7): c.890delT (p.Phe297Serfs) deletion Pathogenic rs886043511 GRCh38 Chromosome 16, 30987963: 30987963
13 HSD3B7 NM_025193.3(HSD3B7): c.196delG (p.Asp66Thrfs) deletion Pathogenic GRCh38 Chromosome 16, 30986078: 30986078
14 HSD3B7 NM_025193.3(HSD3B7): c.196delG (p.Asp66Thrfs) deletion Pathogenic GRCh37 Chromosome 16, 30997399: 30997399

Expression for Bile Acid Synthesis Defect, Congenital, 1

Search GEO for disease gene expression data for Bile Acid Synthesis Defect, Congenital, 1.

Pathways for Bile Acid Synthesis Defect, Congenital, 1

Pathways related to Bile Acid Synthesis Defect, Congenital, 1 according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1 12.07 GRIN2A GRIN2B
2 11.88 GRIN2A GRIN2B
3
Show member pathways
11.82 GRIN2A GRIN2B
4
Show member pathways
11.75 GRIN2A GRIN2B
5
Show member pathways
11.7 GRIN2A GRIN2B
6
Show member pathways
11.57 GRIN2A GRIN2B
7
Show member pathways
11.5 GRIN2A GRIN2B
8
Show member pathways
11.46 GRIN2A GRIN2B
9
Show member pathways
11.33 GRIN2A GRIN2B
10 11.19 GRIN2A GRIN2B
11 10.86 GRIN2A GRIN2B
12 10.62 GRIN2A GRIN2B
13 10.42 GRIN2A GRIN2B
14 9.95 GRIN2A GRIN2B

GO Terms for Bile Acid Synthesis Defect, Congenital, 1

Cellular components related to Bile Acid Synthesis Defect, Congenital, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynaptic density GO:0014069 9.32 GRIN2A GRIN2B
2 postsynaptic membrane GO:0045211 9.26 GRIN2A GRIN2B
3 synaptic membrane GO:0097060 9.16 GRIN2A GRIN2B
4 postsynaptic density membrane GO:0098839 8.96 GRIN2A GRIN2B
5 NMDA selective glutamate receptor complex GO:0017146 8.62 GRIN2A GRIN2B

Biological processes related to Bile Acid Synthesis Defect, Congenital, 1 according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.52 GRIN2A GRIN2B
2 brain development GO:0007420 9.51 GRIN2A GRIN2B
3 MAPK cascade GO:0000165 9.49 GRIN2A GRIN2B
4 response to ethanol GO:0045471 9.48 GRIN2A GRIN2B
5 calcium-mediated signaling GO:0019722 9.46 GRIN2A GRIN2B
6 excitatory postsynaptic potential GO:0060079 9.43 GRIN2A GRIN2B
7 learning or memory GO:0007611 9.4 GRIN2A GRIN2B
8 regulation of synaptic plasticity GO:0048167 9.37 GRIN2A GRIN2B
9 long-term synaptic potentiation GO:0060291 9.32 GRIN2A GRIN2B
10 ionotropic glutamate receptor signaling pathway GO:0035235 9.26 GRIN2A GRIN2B
11 glutamate receptor signaling pathway GO:0007215 9.16 GRIN2A GRIN2B
12 excitatory chemical synaptic transmission GO:0098976 8.96 GRIN2A GRIN2B
13 calcium ion transmembrane import into cytosol GO:0097553 8.62 GRIN2A GRIN2B

Molecular functions related to Bile Acid Synthesis Defect, Congenital, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.37 GRIN2A GRIN2B
2 ion channel activity GO:0005216 9.32 GRIN2A GRIN2B
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.26 GRIN2A GRIN2B
4 ionotropic glutamate receptor activity GO:0004970 9.16 GRIN2A GRIN2B
5 NMDA glutamate receptor activity GO:0004972 8.96 GRIN2A GRIN2B
6 glutamate-gated calcium ion channel activity GO:0022849 8.62 GRIN2A GRIN2B

Sources for Bile Acid Synthesis Defect, Congenital, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....